Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Norvasc (amlodipine by Year
Norvasc (amlodipine — Upjohn spin-off Nov 2020) [legacy] ($M) ($M)
Pfizer Norvasc (amlodipine: $950M in FY2019, down 7.7% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2019
950
Period ended Dec 31, 2019
Change on a year earlier
-7.7%
1,029 in FY2018
History
3 years
Since FY2017
Sources
1
Form 10-K (filed 2020-02-27)
Where the FY2019 figure comes from
Source: Form 10-K (filed 2020-02-27) ↗
Reported in Form 10-K Segment Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Norvasc (amlodipine — Upjohn spin-off Nov 2020) [legacy] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 950 | -7.7% | Form 10-K (filed 2020-02-27) ↗ |
| FY2018 | Dec 31, 2018 | 1,029 | +10.4% | Form 10-K (filed 2020-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 932 | – | Form 10-K (filed 2020-02-27) ↗ |
Cite this data
StockData. (2026). Pfizer Norvasc (amlodipine ($M), annual FY2017–FY2019 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/norvasc-leg
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.